Press release content from Business Wire. The AP news staff was not involved in its creation.
FDA Grants Priority Review to Genentech’s Esbriet (pirfenidone) for Unclassifiable Interstitial Lung Disease
January 21, 2021 GMT
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Jan 21, 2021
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review for Esbriet ® (pirfenidone) for the treatment of unclassifiable interstitial lung disease (UILD). The FDA is expected to make a decision on approval by May 2021.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer
Trishula TherapeuticsJanuary 21, 2021 GMT Trishula Continues to Advance Development of TTX-030 in collaboration with AbbVie
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) Today Trishula Therapeutics, Inc., a clinical stage, privately held company developing TTX-030, a first-in-class anti-CD39 antibody in advanced cancers, announced the appointment of Anil Singhal, Ph.D., MBA, as Chief Executive Officer, effective immediately. Dr. Singhal will also serve on the Trishula Board of Directors.
“The Board of Directors of Trishula Therapeutics is thrilled to bring Anil to the company with his stellar track record in advancing novel oncology therapies from early clinical development through to approval,” said Luke Evnin, Ph.D., Chairman of Trishula’s Board of Directors. “We have complete confidenc
Press release content from Business Wire. The AP news staff was not involved in its creation.
IG Group and tastytrade, Inc. Join Together in $1 Billion Landmark Deal
January 21, 2021 GMT
LONDON & CHICAGO (BUSINESS WIRE) Jan 21, 2021
IG Group Holdings Plc (“IG”), the global online trading platform and tastytrade, Inc. (“tastytrade”), the fast-growing online financial network advocating for and empowering the individual investor, announced today their intention to join forces in a landmark deal. IG is offering tastytrade a total purchase price of $1 billion which excludes tastytrade’s cash. The management teams for IG and tastytrade will remain the same.
ADVERTISEMENT
Both IG and tastytrade have a shared passion for market disruption, innovation, and growth. They are committed to empowering self-directed traders to unlock opportunities in the financial markets and engaging their customers with innovative educational content – a true differentiator in the market. In a
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 .
F-star Therapeutics, Inc.January 20, 2021 GMT
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces the European Patent Office (EPO) has granted a patent with claims protecting the composition of matter of F-star’s FS118 molecule throughout Europe. The expiry date of the patent, not including any potential extensions to the standard 20-year term of protection, is expected to be June 2037.